Skip to main content

Clarification: Aug 6, 2003

Premium

CLARIFICATION — Applied Biosystems is not beta-testing its Expression Array system with Immune Tolerance Networks, a collaborative research effort headquartered at the University of California, San Francisco, the company said last week. The gene expression work Mike Hunkapiller, president of ABI, mentioned during Applera’s fourth-quarter conference call with analysts in regard to Immune Tolerance Network, is the company’s traditional gene-expression analysis conducted with its Taqman chemistry and primers, and Realtime PCR, a company spokeswoman told BioArray News. The company, which declined comment and details on its promised microarray platform, is not releasing the names of beta testers of its microarray platform and will not have any further comment on the platform until it is rolled out, the spokeswoman said.

 

CLARIFICATION — In last week’s report, the mention of Affymetrix Research Lab prototype array capable of handling over 60 million fragments of DNA [Affymetrix annual report, page 14] describes a whole-wafer product, rather than a single chip cut from a wafer, an Affymetrix spokesman told BioArray News.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.